TFEB and Alzheimer disease: For example, increased activity of GSK3β in AD has been reported in many studies, which might contribute to ALP inhibition by promoting TFEB phosphorylation and subsequent cytoplasmic retention (Ly et al., 2013; Li et al., 2016).